Vedolizumab as induction and maintenance therapy for Crohn's disease. - Wikidata - awgldk - TriplyDB

Vedolizumab as induction and maintenance therapy for Crohn's disease.

Vedolizumab as induction and maintenance therapy for Crohn's disease.

http://www.wikidata.org/entity/Q34365574

about

Budesonide for induction of remission in Crohn's disease Vedolizumab for induction and maintenance of remission in ulcerative colitis Oral pathology in inflammatory bowel disease Light and sound - emerging imaging techniques for inflammatory bowel disease.The clinical potential of etrolizumab in ulcerative colitis: hypes and hopes Advances in the development of new biologics in inflammatory bowel disease The role of vedolizumab in patients with moderate-to-severe Crohn's disease and ulcerative colitis Use of biologics and chemotherapy in patients with inflammatory bowel diseases and cancer Selective biologics for ulcerative colitis and Crohn's disease - clinical utility of vedolizumab Vedolizumab: A novel anti-integrin drug for treatment of inflammatory bowel disease Vedolizumab Ustekinumab for the treatment of Crohn's disease: can it find its niche?Integrin-based therapeutics: biological basis, clinical use and new drugs Hepatic manifestations of non-steroidal inflammatory bowel disease therapy Optimizing biologic treatment in IBD: objective measures, but when, how and how often?Current stage in inflammatory bowel disease: What is next?Crohn's disease: a clinical update Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological Treatments Vedolizumab: an α4β7 integrin antagonist for ulcerative colitis and Crohn's disease Pharmacologic therapy for inflammatory bowel disease refractory to steroids Leukocyte integrins: role in leukocyte recruitment and as therapeutic targets in inflammatory disease Tyro3, Axl, and Mertk receptor signaling in inflammatory bowel disease and colitis-associated cancer Therapeutic approaches for celiac disease Review article: anti-adhesion therapies for inflammatory bowel disease Inflammatory pathways of importance for management of inflammatory bowel disease Vedolizumab for inflammatory bowel disease: Changing the game, or more of the same?The multifaceted mast cell in inflammatory bowel disease Ustekinumab in treatment of Crohn's disease: design, development, and potential place in therapy Effectiveness and safety of vedolizumab for treatment of Crohn's disease: a systematic review and meta-analysis THERAPIES FOR CROHN'S DISEASE: a clinical update Interaction of obesity and inflammatory bowel disease Ustekinumab in Crohn's disease: evidence to date and place in therapy The Role of Laboratory Tests in Crohn's Disease Current therapy of pediatric Crohn's disease Next-Generation Therapeutics for IBD Death-associated protein kinase: A molecule with functional antagonistic duality and a potential role in inflammatory bowel disease (Review)Designing biologic selectivity for inflammatory bowel disease--role of vedolizumab Efficacy and safety of antiintegrin antibody for inflammatory bowel disease: a systematic review and meta-analysis Immune System Involvement in the Pathogenesis of JC Virus Induced PML: What is Learned from Studies of Patients with Underlying Diseases and Therapies as Risk Factors Biomarkers as potential treatment targets in inflammatory bowel disease: A systematic review

P2860

Q24187309-9690963F-1E5B-4905-90A8-4104A5C31E91 Q24194423-4FCB6B8A-BC30-47C6-96C2-30BF2EC4B2B8 Q26739055-BAE3B35A-0AFF-4F98-A475-3B0345688F14 Q26739059-E49EA876-81F7-4199-A29B-411859D44DED Q26745725-7A0D4CEC-3B48-4B9A-89DA-DA9C8D6EFDA1 Q26745782-AEC4C02B-3EFB-4F4D-84CD-612494C15FDC Q26748626-A4FF3E79-009B-4658-9B70-97447062FA9F Q26750190-B08F4C2B-D51A-4E8A-B081-5C42B54F8BCF Q26750456-85096BF7-3951-4DD9-8CEE-03CB49382915 Q26752768-346CA3CC-8A95-4209-A14C-B2C3C3B4595C Q26769615-931BA5C6-C4B3-496F-A763-F213F26A46EA Q26771890-DDF13E9E-E8CE-4EC9-A758-039183BEB714 Q26773026-ED119685-A2B0-4BB0-B006-DE27EDFD2E76 Q26773684-A8FDBE1E-5196-445A-8834-D7E58E067B6C Q26775064-7637399B-5DE2-4DBB-8C56-2FD6EC91E64F Q26777429-C1D2771C-B325-4327-8DB4-904B9458B6B8 Q26777696-B64D1FF9-F942-4B95-B96B-FBDB7CC04CBF Q26785537-1417DE6E-A5DB-492C-8B16-08069AFB9579 Q26786018-06D376D2-3A71-4911-85AB-291D7685771F Q26796415-DBD831A1-4B50-4EC3-8198-6E39B23C179D Q26822941-74ACC3F0-D914-43D8-A821-8C03CD0E0522 Q26823237-DBF7D361-8355-4877-820A-420C7141B970 Q26825413-D6F65773-9D58-4D3E-9A12-E177D3766BA3 Q26999705-D38EBF97-F04A-46B3-B525-8DAAEC16E07F Q27005445-CEE42D8C-3339-4B11-A6B4-C6B8AEC42D49 Q27021612-48105819-A98C-4EB6-91CE-D8F83BBC9040 Q27026764-71CF46CC-2465-4005-84A6-7375373C6B0A Q28067631-473F3FD1-503E-4416-B4F8-9ACD255BF436 Q28067760-554D8D85-817C-47BD-BA53-ACC4C1AF14D9 Q28070271-43BB854C-03A9-4F17-87C7-CEFD1041E0C2 Q28072225-5A920820-0883-4701-B31D-FB2B742A3C1E Q28073787-06308AF4-9E8C-4A0C-9B49-654DE24CF80C Q28075045-0C457DA8-08A5-4AE8-AA18-A7B84F2E82B5 Q28081919-108FE475-ADD6-4ABE-9FF7-DFE7462E87DD Q28082306-9969256D-778F-4FD4-A90A-35778FB91899 Q28083490-A8759A2A-9757-44E7-8EB6-5A0DA2A31DDB Q28083872-A05D54A1-A776-4BB6-8AB0-9F0DD078ABB4 Q28084236-1223352F-5336-4BF7-9867-B90C8811362C Q28085415-62564216-A60B-4390-AA9D-0CB6B97C8DC9 Q28087434-FFFD6167-F49E-44B5-84AC-E66535120FFB

P2860

Vedolizumab as induction and maintenance therapy for Crohn's disease.

http://www.wikidata.org/entity/Q34365574

description

2013 nî lūn-bûn

@nan

2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Vedolizumab as induction and maintenance therapy for Crohn's disease.

@ast

Vedolizumab as induction and maintenance therapy for Crohn's disease.

@en

Vedolizumab as induction and maintenance therapy for Crohn's disease.

@nl

type

label

Vedolizumab as induction and maintenance therapy for Crohn's disease.

@ast

Vedolizumab as induction and maintenance therapy for Crohn's disease.

@en

Vedolizumab as induction and maintenance therapy for Crohn's disease.

@nl

prefLabel

Vedolizumab as induction and maintenance therapy for Crohn's disease.

@ast

Vedolizumab as induction and maintenance therapy for Crohn's disease.

@en

Vedolizumab as induction and maintenance therapy for Crohn's disease.

@nl

P1433

Q34365574-B5A7F149-1ED8-46D0-B2FE-E17306430FF6

P1476

Q34365574-EC085CA6-DF38-4F08-85BA-9C31D3B7E49F

P2093

Q34365574-090FE958-6715-413D-B346-F32284CA35AA

Q34365574-108DE783-41C0-43B4-B414-AD9C80131417

Q34365574-18AEC175-1CAE-4E17-83A0-86584B108EB4

Q34365574-1AFB765B-628C-40F5-AF5B-4A134CED79E7

Q34365574-2A0B36AA-E1ED-43B9-B847-76DD569C0C21

Q34365574-3B4C0F2F-7E89-4F91-988F-D2C25C3B35B5

Q34365574-3E7FB702-3B06-4E00-8712-80EA42E7A81A

Q34365574-48F70143-9F52-4D58-B404-3B5BF9503F25

Q34365574-6B162781-D0DF-4AB2-8D25-229587A0A406

Q34365574-E1837192-8CBA-42E8-B293-7067EFFC3935

P304

Q34365574-BB277351-F657-452F-8368-4A92CC9FBFD6

P31

Q34365574-F72DC9BE-E7A6-46D4-A331-165DCD3EB175

P356

Q34365574-3A8B6E56-4942-4CEA-A7F7-0A64D3F5F4DC

P407

Q34365574-CE3784E9-2BB5-4BC6-833B-93F438C2C384

P433

Q34365574-204B1436-1556-4B74-95E8-8D3B5CDAC98B

P478

Q34365574-2387913A-A19F-4CA0-8674-E40803D731CB

P50

Q34365574-01116E3B-6D5C-4866-9DFE-54FAD0FD07B9

Q34365574-4AA0FD8F-DA56-4CE9-956D-21BA9898EBB6

Q34365574-880A0EFF-55DF-4BF6-8DFF-38CBA8506091

Q34365574-A429C5B3-39E4-4945-9C0C-BBD9A1C755CC

Q34365574-C7E33EE4-344D-4428-86FA-3A2DDB0013C9

Q34365574-F84DDFBB-7606-42C9-82DD-F8412200B45B

P577

Q34365574-1DBB15A7-5DB4-4E85-8E3A-C3E0537D9CEC

P698

Q34365574-1D5836D4-D61F-4436-BAEE-F7DA19CF2C57

P921

Q34365574-5126208C-389A-4224-A21A-4E4393867D3F

P356

P1433

The New England Journal of Medicine

P1476

Vedolizumab as induction and maintenance therapy for Crohn's disease.

@en

P2093

Asit Parikh

http://www.w3.org/2001/XMLSchema#string

Brian Bressler

http://www.w3.org/2001/XMLSchema#string

Bruce E Sands

http://www.w3.org/2001/XMLSchema#string

Catherine Milch

http://www.w3.org/2001/XMLSchema#string

GEMINI 2 Study Group

http://www.w3.org/2001/XMLSchema#string

Irving Fox

http://www.w3.org/2001/XMLSchema#string

Jing Xu

http://www.w3.org/2001/XMLSchema#string

Kristin Stephens

http://www.w3.org/2001/XMLSchema#string

Maria Rosario

http://www.w3.org/2001/XMLSchema#string

Scott Lee

http://www.w3.org/2001/XMLSchema#string

P304

711-721

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1215739

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

369

http://www.w3.org/2001/XMLSchema#string

P50

Jean-Frédéric Colombel

Richard N. Fedorak

William Jeffery Sandborn

Brian G. Feagan

P577

2013-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23964933

http://www.w3.org/2001/XMLSchema#string

P921

Crohn's disease